Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

Tianeptine for Treatment-Resistant Depression
Tianeptine for Treatment-Resistant Depression
Sponsor:The Hope for Depression Research Foundation
Enrolling:Male and Female Patients
Study Length:8 Weeks
Age Range:Between 21 and 50 years old
IRB Number:7944
U.S. Government ID:NCT04249596
Contact: Sara Fernandes: 6467748698 / sara.fernandes@nyspi.columbia.edu
Additional Study Information:

The purpose of this 8-week study is to evaluate the effectiveness of a medication called tianeptine for treating depression in people whose symptoms have not responded to two prior treatments. Tianeptine is an investigational drug. This means that it has not been approved for use by the United States Food and Drug Administration (FDA), the branch of the federal government that approves new drugs, but it has been approved by the European Regulatory Agency and has been used to treat depression in Europe, Asia, and South America since the 1980s.

Do You Qualify?
Are you between the ages of 21-50?YesNo
Have you been diagnosed with Major Depressive Disorder?YesNo
Have you tried at least two previous antidepressant treatments that did not work well enough?YesNo
Submit
Cancel
Investigator
Bret Rutherford, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Sara Fernandes
Email: sara.fernandes@nyspi.columbia.edu
Phone: 6467748698